Inferra AIResearch Tools

Inferra AI / Company / PEN

Penumbra Inc.

PEN · Health Care

Last earnings Oct 29, 2026

Key results

Revenuequarter

$354.7 million

Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency 1 , compared to the third quarter of 2024.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

revenue of $275.0 million in the third quarter of 2025, an increase of 21.5% compared to the third quarter of 2024.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Thrombectomy revenuequarter

$192.0 million

Thrombectomy revenue of $192.0 million in the third quarter of 2025, an increase of 18.5% compared to the third quarter of 2024.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

VTE revenuequarter

34%

VTE revenue increased 34% compared to the same period a year ago.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Operating marginquarter

$48.8 million

Income from operations of $48.8 million or operating margin of 13.8% in the third quarter of 2025.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Net incomequarter

$45.9 million

Net income of $45.9 million and adjusted EBITDA 1 of $66.7 million or net income margin of 12.9% and adjusted EBITDA margin 1 of 18.8% in the third quarter of 2025.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Total revenuequarter

$354.7 million

Third Quarter 2025 Financial Results Total revenue increased to $354.7 million for the third quarter of 2025 compared to $301.0 million for the third quarter of 2024, an increase of 17.8%, or 16.9% in constant currency 1 .

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

increased 21.5% while revenue from our international regions increased 6.6%, or 3.0% in constant currency 1 .

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Non-GAAP EPSquarter

30,

diluted EPS for the nine months ended September 30, 2024,

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

AI analysis

Q3 2025 · reported Nov 5, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2025
$354.7M
+17.8% +$54M vs year ago computed from stated figures
EX-99 · Nov 5, 2025
Net income · Q3 2025
$45.9M
EX-99 · Nov 5, 2025
Non-GAAP EPS · Q3 2025
30,
EX-99 · Nov 5, 2025
Thrombectomy revenue · Q3 2025
$192.0M
+1.9% vs prior quarter computed from stated figures
EX-99 · Nov 5, 2025

The quarter in charts

Revenue — quarterly

As stated

0133267400$301.0MSame quarter last year$354.7MQ3 2025

EX-99 · Nov 5, 2025 Statement values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Nov 5, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue$354.7 million$339.5 million$301.0 million
Thrombectomy revenue$192.0 million$188.5 million—
VTE revenue34%42%—
Operating margin$48.8 million$40.8 million—
Net income$45.9 million$45.3 million—
Total revenue$354.7 million$339.5 million$301.0 million
Non-GAAP EPS30,30,—

EX-99 · Nov 5, 2025

Guidance · company-stated

Direction: Raised

Revenue$1 billion

“Updated Full Year 2025 Financial Outlook The Company is increasing its guidance for 2025 total revenue to a range of $1 billion, 375 million to $1 billion, 380 million, which represents 15% to 16% growth over 2024 revenue of $1 billion, 195 million.”

Company outlook — Reiterated

“The Company maintains guidance for U.”

Margin — Reiterated

“The Company also maintains guidance for both gross margin and operating margin for full year 2025.”

Midpoint vs latest-quarter revenue+181.9%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Operating margin$48.8M

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue +181.9% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Reports Third Quarter 2025 Financial Results

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “Updated Full Year 2025 Financial Outlook The Company is increasing its guidance for 2025 total revenue to a range of $1 billion, 375 million to $1 billion, 380 million, which represents 15% to 16% growth over 2024 revenue of $1 billion, 195 million.”

Revenue — Raised (“increasing”)
“Updated Full Year 2025 Financial Outlook The Company is increasing its guidance for 2025 total revenue to a range of $1 billion, 375 million to $1 billion, 380 million, which represents 15% to 16% growth over 2024 revenue of $1 billion, 195 million.”

Company outlook — Reiterated (“maintains”)
“The Company maintains guidance for U.”

Margin — Reiterated (“maintains”)
“The Company also maintains guidance for both gross margin and operating margin for full year 2025.”

Classified from the release's primary full-year outlook statement.

Strategy & priorities

Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

, the world s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Risks & headwinds

The adjustments to the GAAP financial measures reflect the exclusion of the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives the excess tax benefits associated with share-based compensation arrangements non-recurring litigation related expenses non-cash long-lived asset impairment charges related to the impairment of our immersive healthcare asset group and one-time expenses in connection with the wind down of the immersive healthcare business.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

The Company's adjusted EBITDA reflects the exclusion from GAAP net income (loss) of non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes non-recurring litigation related expenses and one-time expenses in connection with the wind down of the immersive healthcare business.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes, non-recurring litigation related expenses, and one-time expenses in connection with the wind down of the immersive healthcare business.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ( SEC ), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

What changed vs prior quarter

Guidance direction — prior quarter: Raised; this quarter: Raised

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Thrombectomy revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Penumbra Inc. — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

34 documents

Earnings releases

13 documents

Presentations

0 documents

No presentations for Penumbra Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Penumbra Inc. are held in this edition of the library.

Mentioned by

7 companies

Other tracked companies whose held documents mention Penumbra Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.